Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Retinal Vein Occlusion - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 07 Dec 17

The "Retinal Vein Occlusion - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Retinal Vein Occlusion - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 3, 9, 2 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Retinal Vein Occlusion - Overview
  3. Retinal Vein Occlusion - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Retinal Vein Occlusion - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Retinal Vein Occlusion - Companies Involved in Therapeutics Development
  • Acucela Inc
  • Addmedica SAS
  • Aerpio Therapeutics Inc
  • Annexin Pharmaceuticals AB
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Clearside BioMedical Inc
  • Formycon AG
  • Graybug Vision Inc
  • Kala Pharmaceuticals Inc
  • Lupin Ltd
  • Mabion SA
  • Novartis AG
  • Ocular Therapeutix Inc
  • Ohr Pharmaceutical Inc
  • Regeneron Pharmaceuticals Inc
  • SciFluor Life Sciences LLC
  • ThromboGenics NV

For more information about this report visit

View source version on

Business Wire

Last updated on: 07/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.